Gelonghui October 31China Biotechnology Services (08037.HK) announced that it is expected that the Group will record a net loss attributable to its owners of approximately HK $65 million in the nine months ended September 30, 2023. Compared with the loss, the Group recorded a net profit attributable to company owners of approximately HK $160 million in the same period in 2022.
The Board is of the view that the loss is mainly due to the decrease in demand for the Group's COVID-19 nucleic acid testing services and rapid antigen test kits following the relaxation of COVID-19 quarantine requirements by the relevant authorities.